In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines to fight infectious diseases, cancer and autoimmune conditions, faster and more efficiently than the industry standard.
